Skip to main content
L

LUMOS DIAGNOSTICS HOLDINGS LIMITED — Investor Relations & Filings

Ticker · LDX ISIN · AU0000157091 LEI · 529900M15QXKTRG8YS81 ASX Manufacturing
Open in API
Filings indexed 508 across all filing types
Latest filing 2026-04-20 Investor Presentation
Country AU Australia
Listing ASX LDX

About LUMOS DIAGNOSTICS HOLDINGS LIMITED

https://lumosdiagnostics.com

Lumos Diagnostics Holdings Limited specializes in the development, manufacturing, and commercialization of rapid point-of-care (POC) diagnostic solutions. The company focuses on improving patient outcomes and supporting antimicrobial stewardship through proprietary diagnostic tests and digital reader platforms. A primary product, FebriDx, is a rapid test designed to differentiate between viral and bacterial respiratory infections within minutes. Beyond its internal product pipeline, the company provides comprehensive contract development and manufacturing organization (CDMO) services. These services support third-party partners in the design, development, and large-scale production of lateral flow assays. Lumos integrates advanced reader technology with assay chemistry to deliver integrated diagnostic systems for clinical and industrial applications.

Recent filings

Filing Released Lang Actions
Q3 FY26 Results Investor Presentation 39 pages 2.1MB
Investor Presentation Classification · 1% confidence The document is titled “Investor Presentation” for Lumos Diagnostics Holdings Limited dated 21 April 2026. It contains detailed slides with disclaimers, forward-looking statements, market data, and terms of an institutional placement and share purchase plan—characteristics of a presentation designed for investors rather than a regulatory report or announcement. It is not a short notice about a report nor an earnings release; it is a full investor presentation. Therefore, it matches the “Investor Presentation” category.
2026-04-20 English
Quarterly Activities/Appendix 4C Cash Flow Report 13 pages 467.2KB
Interim / Quarterly Report Q3 2026
2026-04-19 English
Notification of cessation of securities - LDX 5 pages 16.7KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Listing Rule Appendix 3H “Notification of cessation of securities” for Lumos Diagnostics Holdings Limited. It details the lapse/cancellation of equity-linked securities (performance rights and options) and the resulting change in issued capital. This is not a financial report, insider trade, dividend notice, or buyback; it is a corporate capital change announcement under ASX rules. Therefore it fits the Share Issue/Capital Change category (SHA).
2026-04-15 English
Lumos Q3 FY26 Results Webinar Invitation 2 pages 191.4KB
Report Publication Announcement Classification · 1% confidence The document is an ASX announcement notifying investors of the upcoming Q3 FY26 results release date, inviting them to a webinar, and reminding them of the Share Purchase Plan. It does not contain actual financial results or detailed report content but rather announces the timing of the report and related events. This fits the definition of a Report Publication Announcement (RPA) rather than a full interim report or earnings release.
2026-04-14 English
Lumos receives US$5m FebriDx milestone payment from PHASE 3 pages 386.4KB
Regulatory Filings
2026-04-13 English
Change in substantial holding from RYD 4 pages 225.8KB
Regulatory Filings
2026-04-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.